Munich Reinsurance Co Stock Corp in Munich Has $74.35 Million Stock Position in Eli Lilly and Company $LLY

Munich Reinsurance Co Stock Corp in Munich increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 8.9% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 80,835 shares of the company’s stock after purchasing an additional 6,627 shares during the period. Eli Lilly and Company accounts for approximately 1.8% of Munich Reinsurance Co Stock Corp in Munich’s holdings, making the stock its 17th largest position. Munich Reinsurance Co Stock Corp in Munich’s holdings in Eli Lilly and Company were worth $74,350,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Seelaus Asset Management LLC lifted its position in shares of Eli Lilly and Company by 52.2% in the first quarter. Seelaus Asset Management LLC now owns 659 shares of the company’s stock valued at $566,000 after buying an additional 226 shares during the last quarter. Staley Capital Advisers Inc. acquired a new position in Eli Lilly and Company in the 1st quarter valued at about $288,000. Sageworth Trust Co grew its stake in Eli Lilly and Company by 5.7% in the 1st quarter. Sageworth Trust Co now owns 579 shares of the company’s stock valued at $533,000 after buying an additional 31 shares during the last quarter. Quantum Portfolio Management LLC lifted its position in Eli Lilly and Company by 7.3% during the first quarter. Quantum Portfolio Management LLC now owns 234 shares of the company’s stock worth $215,000 after acquiring an additional 16 shares during the last quarter. Finally, Stenger Family Office LLC boosted its holdings in shares of Eli Lilly and Company by 10.3% during the first quarter. Stenger Family Office LLC now owns 6,375 shares of the company’s stock worth $5,864,000 after acquiring an additional 595 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $1,218.76 on Thursday. The company’s 50-day moving average price is $1,085.08 and its two-hundred day moving average price is $1,031.42. The firm has a market cap of $1.15 trillion, a P/E ratio of 43.30, a P/E/G ratio of 1.54 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, analysts anticipate that Eli Lilly and Company will post 35.7 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 24.58%.

Analysts Set New Price Targets

LLY has been the topic of several research reports. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. BMO Capital Markets restated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Berenberg Bank increased their price objective on Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the stock a “hold” rating in a research report on Monday, June 22nd. Finally, Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the stock an “overweight” rating in a report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $1,255.89.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan and RBC both raised their price targets on Eli Lilly, reinforcing Wall Street’s view that the company still has meaningful upside despite its rich valuation.
• Positive Sentiment: LLY received another boost after its eczema treatment was approved in Canada, adding to the company’s growing non-obesity pipeline and supporting the bull case beyond weight-loss drugs. Article Title
• Positive Sentiment: Several articles highlighted Eli Lilly’s strong GLP-1 and obesity momentum, noting record highs and ongoing investor enthusiasm around Mounjaro, Zepbound, and the broader obesity market.
• Neutral Sentiment: Commentary pieces asked whether it is “too late” to buy LLY and whether the stock is too expensive, but these were largely opinion-driven and did not change the underlying business outlook.
• Neutral Sentiment: Healthcare stocks were broadly weaker late in the day, which may have added some sector-level drag on LLY even as company-specific news remained constructive. Article Title
• Negative Sentiment: Tampa General filed suit against Eli Lilly over pulled 340B discounts, creating a regulatory/legal overhang that could raise investor concerns about drug pricing and hospital reimbursement disputes. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.